Novartis Acquires Avrobio’s $88M Gene Therapy
Purchase leaves biotech’s remaining assets on the table.
Novartis, a global healthcare company, has officially reached an agreement with Avrobio, a biotech organization, to acquire AVR-RD-04, an investigational hematopoietic stem cell gene therapy program for the treatment of the rare genetic condition cystinosis. Per the deal, Novartis will pay $87.5 million without committing milestones or royalties to land the clinical-phase asset. This announcement comes after an initial report of the healthcare company preparing for a full takeover.
The deal represents pressure currently facing Avrobio. With its stock trading below $1 in recent months, the biotech’s ability to raise more money from investors is limited, leading it to identify the Novartis deal as a way to boost its bank balance while narrowing its pipeline.
Reference: Novartis to buy Avrobio gene therapy for $88M, leaving rest of the biotech on the shelf. May 22, 2023/ Fierce Biotech
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
